Form 4: Johnson & Johnson CEO Joaquin Duato Reports Stock Option and Restricted Share Unit Awards

Sentiment:

SEC Form 4 Filing


CEO Joaquin Duato reports the acquisition of stock options and restricted share units under Johnson & Johnson's Long-Term Incentive Plan.

Summary

  • Joaquin Duato, CEO and Chairman of the Board of Johnson & Johnson, filed a Form 4 on February 19, 2025.
  • The filing reports the acquisition of employee stock options and restricted share units (RSUs) awarded under the company's Long-Term Incentive Plan on February 15, 2025.
  • Duato acquired 219,020 stock options with an exercise price of $156.15.
  • These options vest in three equal annual installments starting February 15, 2026, and expire on February 15, 2035.
  • He also acquired 13,513 RSUs, which convert into shares of common stock on a one-for-one basis upon vesting.
  • These RSUs also vest in three equal annual installments beginning February 15, 2026.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, which are generally viewed favorably as they align management interests with shareholder value. There are no red flags or negative aspects presented in the document.

Positives

  • The grant of stock options and RSUs aligns the CEO's interests with those of the shareholders, incentivizing him to improve the company's performance.
  • The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

Stock option and RSU grants are common compensation practices for executives in publicly traded companies, aligning their interests with shareholder value and incentivizing long-term performance.

Comparison to Industry Standards

  • Executive compensation packages, including stock options and RSUs, are standard practice among large-cap companies like Johnson & Johnson.
  • Companies such as Pfizer (PFE) and Merck (MRK) also utilize similar long-term incentive plans for their executives.
  • The vesting schedules and grant sizes are generally benchmarked against peer companies to ensure competitiveness and alignment with performance goals.

Stakeholder Impact

  • Shareholders: The grant of stock options and RSUs aims to align the CEO's interests with shareholder value.
  • Employees: The Long-Term Incentive Plan can contribute to overall employee morale by demonstrating a commitment to rewarding leadership.

Key Dates

DateDescription
02/15/2025Date of the transaction (grant of stock options and RSUs)
02/15/2026First vesting date for both stock options and RSUs
02/15/2035Expiration date of the stock options
02/19/2025Date of Form 4 filing

Keywords

Form 4, Johnson & Johnson, Joaquin Duato, Stock Options, Restricted Share Units, JNJ, Long-Term Incentive Plan, CEO, Chairman of the Board, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.